We gratefully acknowledge the University of California, Berkeley, NIHGMS (R01 GM073932-01), Merck Research Laboratories, Bristol-Myers Squibb, Amgen Inc., DuPont, GlaxoSmithKline, Eli Lilly & Co., Pfizer, AstraZeneca, and Roche for financial support.
1521-3773/asset/2002_left.gif?v=1&s=ac6b0d94a94d7ce7a210002b8096b42feffc0bcf)
1521-3773/asset/2002_right.gif?v=1&s=451042aa3415ae3ad0729984d26dee1866aca82e)
Communication
Total Synthesis of (+)-Fawcettimine†
Article first published online: 29 AUG 2007
DOI: 10.1002/anie.200702695
Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Additional Information
How to Cite
Linghu, X., Kennedy-Smith, J. and Toste, F. (2007), Total Synthesis of (+)-Fawcettimine. Angewandte Chemie International Edition, 46: 7671–7673. doi: 10.1002/anie.200702695
- †
Publication History
- Issue published online: 28 SEP 2007
- Article first published online: 29 AUG 2007
- Manuscript Received: 19 JUN 2007
Funded by
- University of California, Berkeley
- NIHGMS. Grant Number: R01 GM073932-01
- Merck Research Laboratories
- Bristol-Myers Squibb
- Amgen Inc.
- DuPont
- GlaxoSmithKline
- Eli Lilly & Co.
- Pfizer
- AstraZeneca
- Roche
Keywords:
- (+)-fawcettimine;
- alkaloids;
- cyclization;
- gold;
- total synthesis
Graphical Abstract
An effective combination: With the first asymmetric total synthesis of fawcettimine (1) it has been shown that the use of organocatalytic annulation and gold(I)-catalyzed cyclization reactions provides an effective combination for the synthesis of complex molecules. The absolute configuration of 1 was established through an X-ray structure analysis of its hydrobromide.